Protection against Parkinson's disease progression: Clinical experience

被引：43

作者：

LeWittt, Peter A. ^{[1
,2
]}

Taylor, Danette C. ^{[1
,3
]}

机构：

[1] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA

[2] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA

[3] Michigan State Univ, Sch Osteopath Med, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA

来源：

NEUROTHERAPEUTICS | 2008年 / 5卷 / 02期

关键词：

Parkinson's disease; neuroprotection; neurodegeneration; clinical trials; disease modifications;

D O I：

10.1016/j.nurt.2008.01.007

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Treatments with potential neuroprotective capability for Parkinson's disease (PD) have been investigated in randomized, controlled, clinical trials and other studies since the mid-1980s. Although promising leads have arisen, no therapy has been proven to halt or slow disease progression. Several large-scale studies have highlighted progress in methodology, as well as the frustrations of translating laboratory science to practical applications. This review summarizes findings from clinical trials with several classes of compounds, including monoamine oxidase-B inhibitors (selegiline, lazabemide, rasa-giline), dopaminergic drugs (ropinirole, pramipexole, levodopa), antioxidant strategies (a-tocopherol), mitochondrial energy enhancers (coenzyme Q(10), creatine), antiapoptotic agents (TCH346, minocycline, CEP-1347), and antiglutamatergic compounds (riluzole). Beyond small-molecule pharmacology, gene therapy approaches, such as delivering neurotrophic substances (e.g., neurturin) by viral vector, are the next generation of treatment options.

引用

页码：210 / 225

页数：16

共 118 条

[1] Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma [J].

Abramova, NA ;

Cassarino, DS ;

Khan, SM ;

Painter, TW ;

Bennett, JP .

JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 67 (04) :494-500

[2] Neuroprotection in Parkinson models varies with toxin administration protocol [J].

Anderson, David W. ;

Bradbury, Kristin A. ;

Schneider, Jay S. .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 24 (11) :3174-3182

[3] Neuroprotective effects of pramipexole in young and aged MPTP-treated mice [J].

Anderson, DW ;

Neavin, T ;

Smith, JA ;

Schneider, JS .

BRAIN RESEARCH, 2001, 905 (1-2) :44-53

[4]

Andringa G, 2000, ADV RES NEURODEGENER, V8, P215

[5]

[Anonymous], 1995, Arch Neurol, V52, P237

[6]

[Anonymous], 1996, Ann Neurol, V40, P99

[7] Creatine supplementation in Parkinson disease:: A placebo-controlled randomized pilot trial [J].

Bender, A. ;

Koch, W. ;

Elstner, M. ;

Schombacher, Y. ;

Bender, J. ;

Moeschl, M. ;

Gekeler, F. ;

Mueller-Myhsok, B. ;

Gasser, T. ;

Tatsch, K. ;

Klopstock, T. .

NEUROLOGY, 2006, 67 (07) :1262-1264

[8] Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease [J].

Benner, EJ ;

Mosley, RL ;

Destache, CJ ;

Lewis, TB ;

Jackson-Lewis, V ;

Gorantla, S ;

Nemachek, C ;

Green, SR ;

Przedborski, S ;

Gendelman, HE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (25) :9435-9440

[9] Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease [J].

Brooks, DJ ;

Frey, KA ;

Marek, KL ;

Oakes, D ;

Paty, D ;

Prentice, R ;

Shults, CW ;

Stoessl, AJ .

EXPERIMENTAL NEUROLOGY, 2003, 184 :S68-S79

[10]

Camp DM, 2000, J NEUROCHEM, V74, P1229

← 1 2 3 4 5 6 7 8 9 10 →